Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Sarcoma | 90 | 2024 | 1793 | 14.620 |
Why?
|
Retroperitoneal Neoplasms | 53 | 2024 | 332 | 13.220 |
Why?
|
Gastrointestinal Stromal Tumors | 49 | 2024 | 616 | 9.490 |
Why?
|
Soft Tissue Neoplasms | 31 | 2023 | 1156 | 6.720 |
Why?
|
Gastrointestinal Neoplasms | 24 | 2024 | 953 | 4.700 |
Why?
|
Neoplasm Recurrence, Local | 52 | 2023 | 9275 | 2.990 |
Why?
|
Liposarcoma | 18 | 2023 | 285 | 2.550 |
Why?
|
Leiomyosarcoma | 18 | 2023 | 422 | 2.440 |
Why?
|
Fibromatosis, Aggressive | 7 | 2024 | 126 | 1.780 |
Why?
|
Hemangiosarcoma | 9 | 2020 | 215 | 1.720 |
Why?
|
Extremities | 11 | 2022 | 867 | 1.600 |
Why?
|
Nomograms | 6 | 2023 | 228 | 1.310 |
Why?
|
Digestive System Surgical Procedures | 7 | 2016 | 573 | 1.120 |
Why?
|
Antineoplastic Agents | 21 | 2024 | 13635 | 1.080 |
Why?
|
Neoadjuvant Therapy | 16 | 2022 | 2823 | 1.000 |
Why?
|
Combined Modality Therapy | 25 | 2022 | 8526 | 0.960 |
Why?
|
Neoplasms, Radiation-Induced | 4 | 2019 | 549 | 0.940 |
Why?
|
Antineoplastic Agents, Phytogenic | 3 | 2023 | 621 | 0.900 |
Why?
|
Piperazines | 9 | 2013 | 2519 | 0.840 |
Why?
|
Pyrroles | 8 | 2012 | 1126 | 0.770 |
Why?
|
Radiotherapy, Adjuvant | 11 | 2020 | 1784 | 0.770 |
Why?
|
Nephrectomy | 3 | 2022 | 936 | 0.770 |
Why?
|
Rupture, Spontaneous | 2 | 2019 | 362 | 0.770 |
Why?
|
Protein Kinase Inhibitors | 12 | 2024 | 5665 | 0.750 |
Why?
|
Pyrimidines | 9 | 2013 | 3025 | 0.750 |
Why?
|
Prognosis | 42 | 2023 | 29588 | 0.730 |
Why?
|
Survival Rate | 27 | 2024 | 12710 | 0.710 |
Why?
|
Not-For-Profit Insurance Plans | 1 | 2020 | 2 | 0.710 |
Why?
|
United States Department of Defense | 1 | 2020 | 34 | 0.700 |
Why?
|
Humans | 207 | 2024 | 761326 | 0.700 |
Why?
|
Neoplasm Staging | 24 | 2022 | 11098 | 0.680 |
Why?
|
Indoles | 8 | 2012 | 1832 | 0.680 |
Why?
|
Benzamides | 9 | 2013 | 1370 | 0.630 |
Why?
|
Disease-Free Survival | 19 | 2023 | 6815 | 0.600 |
Why?
|
Uterine Neoplasms | 5 | 2017 | 1420 | 0.600 |
Why?
|
Postoperative Complications | 13 | 2022 | 15647 | 0.570 |
Why?
|
Radiotherapy | 5 | 2019 | 1499 | 0.550 |
Why?
|
Fibromatosis, Abdominal | 3 | 2012 | 21 | 0.550 |
Why?
|
Chemotherapy, Adjuvant | 11 | 2020 | 3512 | 0.540 |
Why?
|
Retrospective Studies | 53 | 2023 | 80575 | 0.540 |
Why?
|
Pancreatic Neoplasms | 11 | 2019 | 5363 | 0.530 |
Why?
|
Proto-Oncogene Proteins c-kit | 6 | 2024 | 728 | 0.500 |
Why?
|
Polymers | 3 | 2023 | 1614 | 0.490 |
Why?
|
Rosaniline Dyes | 2 | 2005 | 48 | 0.490 |
Why?
|
Adrenal Glands | 1 | 2017 | 551 | 0.490 |
Why?
|
Middle Aged | 82 | 2024 | 220774 | 0.480 |
Why?
|
Stomach Neoplasms | 5 | 2022 | 1432 | 0.480 |
Why?
|
Aged | 72 | 2024 | 169179 | 0.470 |
Why?
|
Solitary Fibrous Tumors | 3 | 2020 | 67 | 0.470 |
Why?
|
Neoplasm Invasiveness | 7 | 2017 | 3588 | 0.460 |
Why?
|
Postoperative Care | 2 | 2019 | 1471 | 0.440 |
Why?
|
Neoplasms, Second Primary | 2 | 2012 | 1051 | 0.430 |
Why?
|
Brachytherapy | 4 | 2014 | 1223 | 0.420 |
Why?
|
Neoplasm Metastasis | 9 | 2020 | 4908 | 0.420 |
Why?
|
Paclitaxel | 4 | 2023 | 1732 | 0.410 |
Why?
|
Adult | 73 | 2024 | 221122 | 0.410 |
Why?
|
Pancreatectomy | 4 | 2021 | 810 | 0.410 |
Why?
|
Female | 100 | 2024 | 392485 | 0.410 |
Why?
|
Pancreaticoduodenectomy | 4 | 2018 | 508 | 0.410 |
Why?
|
Carcinoma, Intraductal, Noninfiltrating | 2 | 2017 | 926 | 0.400 |
Why?
|
Breast Neoplasms | 12 | 2022 | 21009 | 0.400 |
Why?
|
Protein-Tyrosine Kinases | 3 | 2018 | 2423 | 0.390 |
Why?
|
Pregnancy Complications, Neoplastic | 1 | 2014 | 258 | 0.390 |
Why?
|
Limb Salvage | 3 | 2011 | 481 | 0.380 |
Why?
|
Benzenesulfonates | 1 | 2012 | 166 | 0.380 |
Why?
|
Aged, 80 and over | 33 | 2023 | 58946 | 0.370 |
Why?
|
Gastrectomy | 2 | 2014 | 671 | 0.370 |
Why?
|
Iodine Radioisotopes | 1 | 2014 | 1033 | 0.370 |
Why?
|
Extracellular Fluid | 1 | 2012 | 165 | 0.360 |
Why?
|
Databases, Factual | 5 | 2020 | 7954 | 0.360 |
Why?
|
Endoscopy, Gastrointestinal | 1 | 2017 | 873 | 0.360 |
Why?
|
Skin Neoplasms | 5 | 2022 | 5820 | 0.360 |
Why?
|
SEER Program | 6 | 2019 | 1449 | 0.360 |
Why?
|
Therapies, Investigational | 1 | 2011 | 111 | 0.360 |
Why?
|
Laparoscopy | 2 | 2020 | 2035 | 0.350 |
Why?
|
Markov Chains | 1 | 2013 | 965 | 0.350 |
Why?
|
Male | 80 | 2024 | 360621 | 0.340 |
Why?
|
Follow-Up Studies | 21 | 2021 | 39108 | 0.340 |
Why?
|
Survival Analysis | 11 | 2020 | 10075 | 0.330 |
Why?
|
Colon | 1 | 2017 | 1792 | 0.330 |
Why?
|
Intestinal Neoplasms | 1 | 2012 | 311 | 0.330 |
Why?
|
Population Surveillance | 2 | 2019 | 2603 | 0.330 |
Why?
|
Molecular Targeted Therapy | 4 | 2020 | 2811 | 0.320 |
Why?
|
Chondrosarcoma | 1 | 2011 | 296 | 0.320 |
Why?
|
Hysterectomy | 2 | 2014 | 857 | 0.310 |
Why?
|
Heart Neoplasms | 1 | 2012 | 362 | 0.310 |
Why?
|
Disease Management | 2 | 2016 | 2504 | 0.310 |
Why?
|
Lipoma | 2 | 2017 | 292 | 0.310 |
Why?
|
Salvage Therapy | 2 | 2012 | 1264 | 0.310 |
Why?
|
Histiocytoma, Malignant Fibrous | 1 | 2008 | 55 | 0.300 |
Why?
|
Medical Oncology | 2 | 2021 | 2321 | 0.290 |
Why?
|
Physician Incentive Plans | 1 | 2009 | 164 | 0.290 |
Why?
|
Treatment Outcome | 26 | 2024 | 64645 | 0.290 |
Why?
|
Anaphylaxis | 2 | 2005 | 757 | 0.290 |
Why?
|
Delivery, Obstetric | 1 | 2014 | 940 | 0.280 |
Why?
|
Sciatic Neuropathy | 1 | 2007 | 75 | 0.270 |
Why?
|
Neoplasms | 5 | 2024 | 22158 | 0.270 |
Why?
|
Fasciitis | 1 | 2007 | 67 | 0.260 |
Why?
|
Vascular Neoplasms | 1 | 2007 | 166 | 0.260 |
Why?
|
Patient Acceptance of Health Care | 1 | 2020 | 3204 | 0.260 |
Why?
|
Surgical Procedures, Operative | 2 | 2016 | 1923 | 0.260 |
Why?
|
Intestine, Small | 1 | 2012 | 1205 | 0.260 |
Why?
|
Pancreas | 2 | 2022 | 1689 | 0.260 |
Why?
|
Decision Making | 2 | 2017 | 3929 | 0.250 |
Why?
|
Microsatellite Repeats | 2 | 2004 | 785 | 0.250 |
Why?
|
Kaplan-Meier Estimate | 9 | 2019 | 6473 | 0.250 |
Why?
|
Sentinel Lymph Node Biopsy | 3 | 2022 | 732 | 0.250 |
Why?
|
Histamine H1 Antagonists | 1 | 2005 | 100 | 0.250 |
Why?
|
Early Detection of Cancer | 1 | 2019 | 3200 | 0.240 |
Why?
|
Carcinoid Tumor | 1 | 2006 | 224 | 0.240 |
Why?
|
Adenocarcinoma | 5 | 2019 | 6332 | 0.240 |
Why?
|
Neuroendocrine Tumors | 1 | 2011 | 642 | 0.240 |
Why?
|
Interleukin-8 | 2 | 2004 | 696 | 0.240 |
Why?
|
Incidence | 10 | 2021 | 21336 | 0.230 |
Why?
|
Multiple Endocrine Neoplasia Type 1 | 1 | 2004 | 43 | 0.230 |
Why?
|
Vena Cava, Inferior | 1 | 2007 | 459 | 0.230 |
Why?
|
Healthcare Disparities | 1 | 2020 | 3357 | 0.230 |
Why?
|
Endostatins | 1 | 2004 | 168 | 0.230 |
Why?
|
Kidney Neoplasms | 1 | 2020 | 4246 | 0.230 |
Why?
|
Insulinoma | 1 | 2004 | 121 | 0.220 |
Why?
|
Retroperitoneal Space | 2 | 2022 | 170 | 0.220 |
Why?
|
Tumor Burden | 5 | 2017 | 1887 | 0.220 |
Why?
|
Comprehension | 1 | 2009 | 621 | 0.220 |
Why?
|
Mastectomy, Segmental | 3 | 2017 | 953 | 0.220 |
Why?
|
Liposarcoma, Myxoid | 1 | 2023 | 60 | 0.220 |
Why?
|
Length of Stay | 3 | 2022 | 6422 | 0.220 |
Why?
|
Risk Factors | 13 | 2022 | 74152 | 0.210 |
Why?
|
Naphthyridines | 1 | 2024 | 143 | 0.210 |
Why?
|
Apoptosis | 6 | 2022 | 9474 | 0.210 |
Why?
|
Hyperparathyroidism | 1 | 2004 | 337 | 0.210 |
Why?
|
Rare Diseases | 3 | 2021 | 621 | 0.210 |
Why?
|
Adenocarcinoma, Mucinous | 2 | 2008 | 517 | 0.210 |
Why?
|
Cyclooxygenase Inhibitors | 1 | 2004 | 361 | 0.210 |
Why?
|
Parathyroid Neoplasms | 1 | 2004 | 242 | 0.210 |
Why?
|
Duodenal Neoplasms | 2 | 2013 | 115 | 0.200 |
Why?
|
Ganglioneuroma | 1 | 2022 | 53 | 0.200 |
Why?
|
Pelvic Neoplasms | 1 | 2024 | 247 | 0.200 |
Why?
|
Pheochromocytoma | 1 | 2004 | 328 | 0.200 |
Why?
|
Kidney | 1 | 2017 | 7049 | 0.200 |
Why?
|
Age Factors | 4 | 2022 | 18401 | 0.200 |
Why?
|
Mice, Nude | 6 | 2019 | 3603 | 0.200 |
Why?
|
Urea | 1 | 2024 | 444 | 0.190 |
Why?
|
Succinate Dehydrogenase | 2 | 2019 | 145 | 0.190 |
Why?
|
Biopsy, Needle | 2 | 2006 | 1626 | 0.190 |
Why?
|
Young Adult | 18 | 2021 | 59196 | 0.190 |
Why?
|
Popliteal Artery | 1 | 2003 | 310 | 0.190 |
Why?
|
General Surgery | 2 | 2012 | 1692 | 0.190 |
Why?
|
Models, Economic | 2 | 2017 | 716 | 0.190 |
Why?
|
Pyridines | 2 | 2019 | 2870 | 0.190 |
Why?
|
Doxorubicin | 3 | 2022 | 2215 | 0.180 |
Why?
|
Phyllodes Tumor | 1 | 2021 | 53 | 0.180 |
Why?
|
Fellowships and Scholarships | 2 | 2020 | 1117 | 0.180 |
Why?
|
Genetic Predisposition to Disease | 2 | 2019 | 17872 | 0.180 |
Why?
|
Hemangioendothelioma, Epithelioid | 1 | 2021 | 53 | 0.180 |
Why?
|
Carcinoma, Papillary | 1 | 2006 | 784 | 0.180 |
Why?
|
Biological Products | 2 | 2022 | 913 | 0.180 |
Why?
|
Nevus, Blue | 1 | 2020 | 43 | 0.180 |
Why?
|
Genomic Instability | 1 | 2004 | 709 | 0.180 |
Why?
|
Risk Assessment | 5 | 2017 | 23981 | 0.180 |
Why?
|
Diagnostic Imaging | 3 | 2011 | 3531 | 0.180 |
Why?
|
Hemangiopericytoma | 1 | 2020 | 71 | 0.180 |
Why?
|
Aneurysm | 1 | 2003 | 337 | 0.180 |
Why?
|
Tropomyosin | 1 | 2020 | 104 | 0.180 |
Why?
|
Mitotic Index | 3 | 2020 | 161 | 0.170 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 6 | 2019 | 11735 | 0.170 |
Why?
|
Endosonography | 2 | 2008 | 610 | 0.170 |
Why?
|
Neovascularization, Pathologic | 3 | 2005 | 2644 | 0.170 |
Why?
|
Renal Replacement Therapy | 1 | 2022 | 282 | 0.170 |
Why?
|
Hodgkin Disease | 1 | 2007 | 1378 | 0.160 |
Why?
|
Germany | 2 | 2024 | 875 | 0.160 |
Why?
|
Adrenal Gland Neoplasms | 1 | 2004 | 732 | 0.160 |
Why?
|
Randomized Controlled Trials as Topic | 6 | 2021 | 10203 | 0.160 |
Why?
|
Pathology, Clinical | 1 | 2022 | 375 | 0.160 |
Why?
|
Academic Medical Centers | 1 | 2009 | 2760 | 0.160 |
Why?
|
DNA Polymerase II | 1 | 2019 | 104 | 0.160 |
Why?
|
Bone Neoplasms | 2 | 2021 | 2527 | 0.160 |
Why?
|
Receptors, Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2018 | 114 | 0.150 |
Why?
|
Practice Guidelines as Topic | 5 | 2020 | 7389 | 0.150 |
Why?
|
Splenectomy | 2 | 2018 | 391 | 0.150 |
Why?
|
Videoconferencing | 1 | 2020 | 203 | 0.150 |
Why?
|
Consensus | 7 | 2022 | 3122 | 0.150 |
Why?
|
Abdomen | 2 | 2022 | 1128 | 0.150 |
Why?
|
Registries | 3 | 2024 | 8223 | 0.150 |
Why?
|
Oncogenes | 2 | 2020 | 1223 | 0.140 |
Why?
|
Mutation | 10 | 2024 | 30044 | 0.140 |
Why?
|
Neoplasm, Residual | 4 | 2017 | 1008 | 0.140 |
Why?
|
Quality of Life | 1 | 2018 | 13355 | 0.140 |
Why?
|
Mice | 12 | 2023 | 81474 | 0.140 |
Why?
|
Hematologic Neoplasms | 1 | 2008 | 1896 | 0.140 |
Why?
|
North America | 2 | 2020 | 1275 | 0.140 |
Why?
|
Upper Extremity | 2 | 2012 | 657 | 0.140 |
Why?
|
Critical Pathways | 1 | 2020 | 474 | 0.140 |
Why?
|
Uterus | 1 | 2020 | 649 | 0.130 |
Why?
|
Europe | 3 | 2020 | 3420 | 0.130 |
Why?
|
Xenograft Model Antitumor Assays | 4 | 2019 | 3590 | 0.130 |
Why?
|
Graft vs Host Disease | 1 | 2008 | 3030 | 0.130 |
Why?
|
Glucocorticoids | 1 | 2005 | 2163 | 0.130 |
Why?
|
London | 1 | 2016 | 234 | 0.130 |
Why?
|
Poland | 1 | 2016 | 198 | 0.130 |
Why?
|
Vascular Surgical Procedures | 2 | 2004 | 1490 | 0.130 |
Why?
|
Adrenalectomy | 1 | 2017 | 346 | 0.130 |
Why?
|
Tumor Cells, Cultured | 3 | 2011 | 6128 | 0.120 |
Why?
|
History, 19th Century | 1 | 2017 | 720 | 0.120 |
Why?
|
Sarcoma, Alveolar Soft Part | 1 | 2015 | 43 | 0.120 |
Why?
|
Disease Progression | 8 | 2022 | 13500 | 0.120 |
Why?
|
Ontario | 1 | 2016 | 399 | 0.120 |
Why?
|
Endothelial Cells | 2 | 2004 | 3543 | 0.120 |
Why?
|
Sulfonamides | 1 | 2004 | 1976 | 0.120 |
Why?
|
Morbidity | 4 | 2021 | 1750 | 0.120 |
Why?
|
Catheter Ablation | 2 | 2005 | 2752 | 0.120 |
Why?
|
Liver Cirrhosis | 1 | 2005 | 1934 | 0.120 |
Why?
|
Carcinoma, Pancreatic Ductal | 1 | 2006 | 1726 | 0.120 |
Why?
|
Cell Line, Tumor | 5 | 2023 | 16966 | 0.120 |
Why?
|
Sarcoma, Clear Cell | 1 | 2015 | 72 | 0.120 |
Why?
|
Biological Specimen Banks | 1 | 2020 | 783 | 0.120 |
Why?
|
Recombinant Proteins | 1 | 2004 | 6525 | 0.120 |
Why?
|
Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 1 | 2017 | 318 | 0.120 |
Why?
|
Time Factors | 10 | 2019 | 39974 | 0.120 |
Why?
|
Tomography, X-Ray Computed | 11 | 2023 | 20555 | 0.120 |
Why?
|
Pyrazoles | 1 | 2004 | 2007 | 0.120 |
Why?
|
Neuroblastoma | 1 | 2022 | 1250 | 0.110 |
Why?
|
Carcinoma, Small Cell | 1 | 2016 | 420 | 0.110 |
Why?
|
Biopsy | 3 | 2022 | 6768 | 0.110 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2017 | 696 | 0.110 |
Why?
|
Adolescent | 14 | 2021 | 88305 | 0.110 |
Why?
|
Italy | 2 | 2014 | 841 | 0.110 |
Why?
|
Animals | 15 | 2024 | 168388 | 0.110 |
Why?
|
Disease Models, Animal | 2 | 2022 | 18234 | 0.110 |
Why?
|
Phenylurea Compounds | 2 | 2019 | 529 | 0.110 |
Why?
|
Fibrosarcoma | 2 | 2017 | 308 | 0.110 |
Why?
|
Glomerular Filtration Rate | 1 | 2022 | 2176 | 0.110 |
Why?
|
Chromosome Aberrations | 1 | 2019 | 1771 | 0.110 |
Why?
|
Organs at Risk | 1 | 2015 | 359 | 0.110 |
Why?
|
Music | 1 | 2015 | 245 | 0.110 |
Why?
|
Genital Neoplasms, Male | 1 | 2013 | 68 | 0.110 |
Why?
|
Dystrophin | 1 | 2014 | 283 | 0.100 |
Why?
|
Professional Role | 1 | 2015 | 314 | 0.100 |
Why?
|
Radiotherapy Dosage | 5 | 2015 | 2898 | 0.100 |
Why?
|
Skin | 2 | 2019 | 4482 | 0.100 |
Why?
|
International Classification of Diseases | 1 | 2018 | 909 | 0.100 |
Why?
|
Interviews as Topic | 1 | 2020 | 2696 | 0.100 |
Why?
|
Hospitals | 2 | 2022 | 3878 | 0.100 |
Why?
|
Carcinoma, Hepatocellular | 1 | 2005 | 2299 | 0.100 |
Why?
|
Cost-Benefit Analysis | 2 | 2017 | 5492 | 0.100 |
Why?
|
Career Choice | 1 | 2019 | 756 | 0.100 |
Why?
|
Iodide Peroxidase | 1 | 2014 | 294 | 0.100 |
Why?
|
Colectomy | 1 | 2017 | 688 | 0.100 |
Why?
|
Smooth Muscle Tumor | 1 | 2012 | 63 | 0.100 |
Why?
|
Mediator Complex | 1 | 2012 | 106 | 0.100 |
Why?
|
Fibroblast Growth Factor 2 | 2 | 2004 | 591 | 0.100 |
Why?
|
Liver Neoplasms | 2 | 2005 | 4321 | 0.100 |
Why?
|
Radiation Injuries | 1 | 2019 | 1189 | 0.100 |
Why?
|
Biopsy, Fine-Needle | 2 | 2008 | 1118 | 0.100 |
Why?
|
Proportional Hazards Models | 5 | 2022 | 12450 | 0.100 |
Why?
|
Prospective Studies | 9 | 2022 | 54405 | 0.100 |
Why?
|
Rectum | 1 | 2016 | 892 | 0.100 |
Why?
|
International Cooperation | 2 | 2021 | 1428 | 0.100 |
Why?
|
Muscular Dystrophies | 1 | 2014 | 390 | 0.100 |
Why?
|
Preoperative Care | 4 | 2015 | 2242 | 0.100 |
Why?
|
Angiogenic Proteins | 1 | 2012 | 101 | 0.100 |
Why?
|
Medical Staff, Hospital | 1 | 2015 | 601 | 0.100 |
Why?
|
Endpoint Determination | 1 | 2014 | 590 | 0.100 |
Why?
|
History, 21st Century | 1 | 2017 | 1567 | 0.100 |
Why?
|
Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2015 | 892 | 0.100 |
Why?
|
Meningeal Neoplasms | 1 | 2020 | 1248 | 0.090 |
Why?
|
Chemotherapy, Cancer, Regional Perfusion | 1 | 2011 | 94 | 0.090 |
Why?
|
Statistics, Nonparametric | 1 | 2017 | 2853 | 0.090 |
Why?
|
Thyroid Hormones | 1 | 2014 | 404 | 0.090 |
Why?
|
Netherlands | 1 | 2016 | 2220 | 0.090 |
Why?
|
Vascular Diseases | 1 | 2019 | 1161 | 0.090 |
Why?
|
PTEN Phosphohydrolase | 1 | 2017 | 1114 | 0.090 |
Why?
|
Carcinoma | 1 | 2022 | 2328 | 0.090 |
Why?
|
Physicians | 1 | 2009 | 4591 | 0.090 |
Why?
|
Patient Participation | 1 | 2020 | 1443 | 0.090 |
Why?
|
Gene Expression Profiling | 4 | 2020 | 9414 | 0.090 |
Why?
|
DNA Mutational Analysis | 5 | 2020 | 4108 | 0.090 |
Why?
|
United States | 8 | 2020 | 72317 | 0.090 |
Why?
|
Vascular Endothelial Growth Factors | 1 | 2012 | 748 | 0.090 |
Why?
|
Hematopoietic Stem Cell Transplantation | 1 | 2008 | 5670 | 0.090 |
Why?
|
Confidence Intervals | 1 | 2016 | 2927 | 0.090 |
Why?
|
Peritoneal Neoplasms | 2 | 2008 | 711 | 0.090 |
Why?
|
Magnetic Resonance Imaging | 7 | 2023 | 36430 | 0.090 |
Why?
|
Safety | 1 | 2014 | 1150 | 0.090 |
Why?
|
Vascular Endothelial Growth Factor Receptor-2 | 2 | 2020 | 546 | 0.080 |
Why?
|
Niacinamide | 1 | 2012 | 413 | 0.080 |
Why?
|
Connective Tissue | 2 | 2022 | 419 | 0.080 |
Why?
|
History, 20th Century | 1 | 2017 | 2770 | 0.080 |
Why?
|
Endometrial Neoplasms | 1 | 2019 | 1365 | 0.080 |
Why?
|
Cell Transformation, Neoplastic | 1 | 2019 | 2821 | 0.080 |
Why?
|
Drug Resistance, Neoplasm | 3 | 2024 | 5297 | 0.080 |
Why?
|
Operating Rooms | 1 | 2015 | 790 | 0.080 |
Why?
|
Hypothyroidism | 1 | 2014 | 667 | 0.080 |
Why?
|
Pleural Neoplasms | 1 | 2014 | 609 | 0.080 |
Why?
|
Radiation Oncology | 1 | 2015 | 563 | 0.080 |
Why?
|
Neoplasms, Multiple Primary | 1 | 2013 | 591 | 0.080 |
Why?
|
Pressure | 1 | 2012 | 1155 | 0.080 |
Why?
|
Immunotherapy | 1 | 2024 | 4649 | 0.080 |
Why?
|
Capillary Permeability | 1 | 2012 | 774 | 0.080 |
Why?
|
Patient Preference | 1 | 2015 | 926 | 0.080 |
Why?
|
Base Pair Mismatch | 2 | 2004 | 92 | 0.070 |
Why?
|
Hyperthermia, Induced | 1 | 2011 | 417 | 0.070 |
Why?
|
Colorectal Neoplasms | 2 | 2004 | 6901 | 0.070 |
Why?
|
Multivariate Analysis | 3 | 2017 | 12059 | 0.070 |
Why?
|
Leiomyoma | 1 | 2012 | 636 | 0.070 |
Why?
|
Rectal Neoplasms | 1 | 2016 | 1157 | 0.070 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2018 | 10764 | 0.070 |
Why?
|
Mesentery | 1 | 2008 | 202 | 0.070 |
Why?
|
Renal Insufficiency, Chronic | 1 | 2022 | 2241 | 0.070 |
Why?
|
Cell Proliferation | 3 | 2019 | 10431 | 0.070 |
Why?
|
Lower Extremity | 2 | 2012 | 1201 | 0.070 |
Why?
|
Estrogen Replacement Therapy | 1 | 2014 | 1208 | 0.070 |
Why?
|
Cancer Vaccines | 1 | 2015 | 1050 | 0.070 |
Why?
|
Paraganglioma | 1 | 2009 | 142 | 0.070 |
Why?
|
Skin Transplantation | 1 | 2012 | 1083 | 0.070 |
Why?
|
Cohort Studies | 7 | 2024 | 41440 | 0.070 |
Why?
|
Estrogens | 1 | 2014 | 1521 | 0.070 |
Why?
|
Gastrointestinal Diseases | 1 | 2015 | 1198 | 0.070 |
Why?
|
Takotsubo Cardiomyopathy | 1 | 2009 | 123 | 0.070 |
Why?
|
Terminology as Topic | 1 | 2014 | 1535 | 0.070 |
Why?
|
Contrast Media | 4 | 2014 | 5310 | 0.070 |
Why?
|
Genomics | 2 | 2020 | 5817 | 0.070 |
Why?
|
Malignant Carcinoid Syndrome | 1 | 2006 | 30 | 0.070 |
Why?
|
Video Recording | 1 | 2012 | 966 | 0.070 |
Why?
|
Lymph Nodes | 2 | 2022 | 3469 | 0.070 |
Why?
|
Respiratory Tract Neoplasms | 1 | 2006 | 56 | 0.070 |
Why?
|
Education, Medical, Continuing | 1 | 2012 | 824 | 0.070 |
Why?
|
Radiotherapy Planning, Computer-Assisted | 1 | 2015 | 1661 | 0.070 |
Why?
|
Pancreatic Diseases | 1 | 2008 | 343 | 0.070 |
Why?
|
Treatment Failure | 2 | 2014 | 2642 | 0.060 |
Why?
|
Efficiency | 1 | 2009 | 476 | 0.060 |
Why?
|
Diabetes Complications | 1 | 2012 | 1317 | 0.060 |
Why?
|
Receptor, Platelet-Derived Growth Factor alpha | 2 | 2018 | 367 | 0.060 |
Why?
|
Laparotomy | 1 | 2008 | 457 | 0.060 |
Why?
|
Immunohistochemistry | 4 | 2020 | 11070 | 0.060 |
Why?
|
Electronic Health Records | 1 | 2022 | 4812 | 0.060 |
Why?
|
Group IV Phospholipases A2 | 1 | 2004 | 58 | 0.060 |
Why?
|
Carcinoma, Ductal, Breast | 1 | 2012 | 1085 | 0.060 |
Why?
|
Phospholipases A2 | 1 | 2004 | 197 | 0.060 |
Why?
|
Pancreatic Cyst | 1 | 2008 | 367 | 0.060 |
Why?
|
Mesenteric Veins | 1 | 2004 | 86 | 0.060 |
Why?
|
DNA Sequence, Unstable | 1 | 2004 | 1 | 0.060 |
Why?
|
Technetium Tc 99m Sulfur Colloid | 1 | 2004 | 63 | 0.060 |
Why?
|
Indomethacin | 1 | 2004 | 326 | 0.060 |
Why?
|
Phospholipases A | 1 | 2004 | 204 | 0.060 |
Why?
|
Evidence-Based Medicine | 2 | 2020 | 3687 | 0.060 |
Why?
|
Mastectomy | 1 | 2012 | 1822 | 0.060 |
Why?
|
Surgical Flaps | 1 | 2012 | 1671 | 0.060 |
Why?
|
Prostaglandin-Endoperoxide Synthases | 1 | 2004 | 318 | 0.060 |
Why?
|
Proteins | 1 | 2019 | 6034 | 0.060 |
Why?
|
Diagnosis, Differential | 4 | 2020 | 12972 | 0.060 |
Why?
|
Canada | 2 | 2020 | 2120 | 0.050 |
Why?
|
Decision Support Techniques | 1 | 2013 | 1998 | 0.050 |
Why?
|
Positron-Emission Tomography | 3 | 2013 | 6478 | 0.050 |
Why?
|
Vascular Endothelial Growth Factor A | 2 | 2004 | 3489 | 0.050 |
Why?
|
Pregnancy Outcome | 1 | 2014 | 2920 | 0.050 |
Why?
|
Clinical Competence | 1 | 2019 | 4793 | 0.050 |
Why?
|
Boston | 1 | 2016 | 9333 | 0.050 |
Why?
|
Acute Disease | 2 | 2015 | 7238 | 0.050 |
Why?
|
Proto-Oncogene Proteins c-akt | 1 | 2011 | 2453 | 0.050 |
Why?
|
Cyclooxygenase 2 Inhibitors | 1 | 2004 | 321 | 0.050 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3080 | 0.050 |
Why?
|
Intraoperative Care | 1 | 2006 | 766 | 0.050 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3200 | 0.050 |
Why?
|
Feasibility Studies | 2 | 2012 | 5247 | 0.050 |
Why?
|
Prevalence | 1 | 2019 | 15719 | 0.050 |
Why?
|
Cyclin-Dependent Kinase 2 | 1 | 2022 | 184 | 0.050 |
Why?
|
Cyclooxygenase 2 | 1 | 2004 | 597 | 0.050 |
Why?
|
Lung Neoplasms | 2 | 2018 | 13333 | 0.050 |
Why?
|
Portal Vein | 1 | 2004 | 431 | 0.050 |
Why?
|
Melanoma | 1 | 2020 | 5706 | 0.050 |
Why?
|
Dinoprostone | 1 | 2004 | 597 | 0.050 |
Why?
|
Propensity Score | 2 | 2020 | 1908 | 0.050 |
Why?
|
Attitude of Health Personnel | 1 | 2015 | 3889 | 0.050 |
Why?
|
Predictive Value of Tests | 3 | 2009 | 15262 | 0.050 |
Why?
|
Drug Therapy | 1 | 2004 | 503 | 0.050 |
Why?
|
Wound Healing | 1 | 2012 | 2802 | 0.050 |
Why?
|
Ultrasonography, Mammary | 2 | 2014 | 239 | 0.050 |
Why?
|
Immunoenzyme Techniques | 1 | 2004 | 1704 | 0.050 |
Why?
|
Triazoles | 2 | 2019 | 903 | 0.050 |
Why?
|
MART-1 Antigen | 1 | 2020 | 65 | 0.050 |
Why?
|
Inflammation | 1 | 2020 | 10760 | 0.040 |
Why?
|
Solitary Fibrous Tumor, Pleural | 1 | 2020 | 25 | 0.040 |
Why?
|
Sensitivity and Specificity | 4 | 2018 | 14665 | 0.040 |
Why?
|
Pandemics | 1 | 2020 | 8635 | 0.040 |
Why?
|
Tumor Microenvironment | 2 | 2024 | 3873 | 0.040 |
Why?
|
Fibroblast Growth Factor 4 | 1 | 2019 | 28 | 0.040 |
Why?
|
Biology | 1 | 2022 | 289 | 0.040 |
Why?
|
Pancreatic Fistula | 1 | 2021 | 148 | 0.040 |
Why?
|
S100 Proteins | 1 | 2020 | 218 | 0.040 |
Why?
|
DNA Methylation | 3 | 2019 | 4383 | 0.040 |
Why?
|
Nanoparticles | 1 | 2011 | 1955 | 0.040 |
Why?
|
Radiopharmaceuticals | 2 | 2013 | 2650 | 0.040 |
Why?
|
Cyclin-Dependent Kinase 6 | 1 | 2022 | 347 | 0.040 |
Why?
|
Clinical Protocols | 1 | 2005 | 1440 | 0.040 |
Why?
|
Receptor, trkA | 1 | 2020 | 159 | 0.040 |
Why?
|
Postoperative Period | 2 | 2018 | 1813 | 0.040 |
Why?
|
Authorship | 1 | 2022 | 284 | 0.040 |
Why?
|
HEK293 Cells | 2 | 2019 | 4280 | 0.040 |
Why?
|
Receptors, Fibroblast Growth Factor | 1 | 2019 | 191 | 0.040 |
Why?
|
Patient Advocacy | 1 | 2021 | 360 | 0.040 |
Why?
|
Cyclin-Dependent Kinase 4 | 1 | 2022 | 559 | 0.040 |
Why?
|
Internship and Residency | 1 | 2019 | 5877 | 0.040 |
Why?
|
Transcription Factors | 1 | 2018 | 12122 | 0.040 |
Why?
|
DNA Repair | 2 | 2004 | 2044 | 0.040 |
Why?
|
Research Design | 1 | 2014 | 6178 | 0.040 |
Why?
|
Nevus, Pigmented | 1 | 2020 | 221 | 0.040 |
Why?
|
Personnel Selection | 1 | 2020 | 196 | 0.040 |
Why?
|
Omentum | 1 | 2019 | 168 | 0.040 |
Why?
|
Drug Administration Schedule | 1 | 2006 | 4850 | 0.040 |
Why?
|
Observer Variation | 2 | 2015 | 2605 | 0.040 |
Why?
|
Antineoplastic Agents, Hormonal | 1 | 2006 | 1519 | 0.040 |
Why?
|
Lymphatic Metastasis | 2 | 2018 | 2914 | 0.040 |
Why?
|
Gene Expression | 2 | 2022 | 7582 | 0.040 |
Why?
|
Cell Differentiation | 2 | 2014 | 11531 | 0.040 |
Why?
|
Adenosine Triphosphate | 1 | 2024 | 1989 | 0.040 |
Why?
|
Gene Fusion | 1 | 2020 | 356 | 0.040 |
Why?
|
Multicenter Studies as Topic | 1 | 2022 | 1703 | 0.040 |
Why?
|
Analysis of Variance | 2 | 2020 | 6231 | 0.040 |
Why?
|
Ubiquitin Thiolesterase | 1 | 2020 | 455 | 0.040 |
Why?
|
Risk | 1 | 2009 | 9605 | 0.040 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2021 | 857 | 0.040 |
Why?
|
Radiotherapy, Conformal | 1 | 2020 | 548 | 0.040 |
Why?
|
Cricetulus | 1 | 2019 | 815 | 0.040 |
Why?
|
Melanocytes | 1 | 2020 | 509 | 0.040 |
Why?
|
Azepines | 1 | 2019 | 329 | 0.030 |
Why?
|
Chromosomes, Human, Pair 14 | 1 | 2017 | 287 | 0.030 |
Why?
|
Genetic Markers | 2 | 2020 | 2612 | 0.030 |
Why?
|
Clinical Trials, Phase II as Topic | 1 | 2019 | 628 | 0.030 |
Why?
|
CHO Cells | 1 | 2019 | 1389 | 0.030 |
Why?
|
Cell Cycle | 2 | 2017 | 2930 | 0.030 |
Why?
|
Benchmarking | 1 | 2022 | 1045 | 0.030 |
Why?
|
Carboplatin | 1 | 2019 | 794 | 0.030 |
Why?
|
Lipopolysaccharides | 1 | 2023 | 2206 | 0.030 |
Why?
|
Infarction | 1 | 2017 | 248 | 0.030 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 1 | 2020 | 898 | 0.030 |
Why?
|
Neurofibromin 1 | 1 | 2017 | 190 | 0.030 |
Why?
|
Gene Silencing | 2 | 2017 | 1509 | 0.030 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 1 | 2004 | 2273 | 0.030 |
Why?
|
Blotting, Western | 2 | 2012 | 5034 | 0.030 |
Why?
|
Texas | 2 | 2007 | 405 | 0.030 |
Why?
|
Interstitial Cells of Cajal | 1 | 2014 | 23 | 0.030 |
Why?
|
Reactive Oxygen Species | 1 | 2022 | 2137 | 0.030 |
Why?
|
Health Resources | 1 | 2020 | 935 | 0.030 |
Why?
|
Sequence Analysis, RNA | 1 | 2022 | 2019 | 0.030 |
Why?
|
Salpingectomy | 1 | 2014 | 45 | 0.030 |
Why?
|
Meta-Analysis as Topic | 1 | 2019 | 1376 | 0.030 |
Why?
|
Wiskott-Aldrich Syndrome | 1 | 1994 | 130 | 0.030 |
Why?
|
Program Development | 1 | 2020 | 1298 | 0.030 |
Why?
|
Genital Neoplasms, Female | 1 | 2019 | 532 | 0.030 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2017 | 12144 | 0.030 |
Why?
|
Data Collection | 1 | 2022 | 3324 | 0.030 |
Why?
|
Osteosarcoma | 1 | 2019 | 896 | 0.030 |
Why?
|
Enhancer Elements, Genetic | 1 | 2019 | 1363 | 0.030 |
Why?
|
Drug Delivery Systems | 1 | 2024 | 2223 | 0.030 |
Why?
|
Endothelium, Vascular | 1 | 2005 | 4432 | 0.030 |
Why?
|
Necrosis | 1 | 2017 | 1605 | 0.030 |
Why?
|
Employment | 1 | 2019 | 1118 | 0.030 |
Why?
|
Muscle Development | 1 | 2014 | 259 | 0.030 |
Why?
|
Mammography | 2 | 2014 | 2429 | 0.030 |
Why?
|
Oncogene Proteins, Fusion | 1 | 2020 | 1605 | 0.030 |
Why?
|
Chromosome Deletion | 1 | 2017 | 1387 | 0.030 |
Why?
|
Pregnancy | 1 | 2014 | 29858 | 0.020 |
Why?
|
Basic Helix-Loop-Helix Transcription Factors | 1 | 2018 | 1135 | 0.020 |
Why?
|
Repetitive Sequences, Nucleic Acid | 1 | 1994 | 783 | 0.020 |
Why?
|
Faculty, Medical | 1 | 2020 | 1202 | 0.020 |
Why?
|
Ovariectomy | 1 | 2014 | 614 | 0.020 |
Why?
|
Neoplasms, Hormone-Dependent | 1 | 2014 | 410 | 0.020 |
Why?
|
Rhabdomyosarcoma | 1 | 2014 | 358 | 0.020 |
Why?
|
Multigene Family | 1 | 1994 | 1077 | 0.020 |
Why?
|
Radiography, Abdominal | 1 | 2014 | 534 | 0.020 |
Why?
|
Receptor Protein-Tyrosine Kinases | 1 | 2018 | 1624 | 0.020 |
Why?
|
X Chromosome | 1 | 1994 | 816 | 0.020 |
Why?
|
Severity of Illness Index | 1 | 2008 | 15835 | 0.020 |
Why?
|
Quality-Adjusted Life Years | 1 | 2017 | 1722 | 0.020 |
Why?
|
Delphi Technique | 1 | 2014 | 846 | 0.020 |
Why?
|
Duodenum | 1 | 2013 | 489 | 0.020 |
Why?
|
Tumor Suppressor Proteins | 1 | 2020 | 2804 | 0.020 |
Why?
|
Aromatase Inhibitors | 1 | 2014 | 513 | 0.020 |
Why?
|
Learning Curve | 1 | 2012 | 230 | 0.020 |
Why?
|
Kidney Calculi | 1 | 1994 | 463 | 0.020 |
Why?
|
Fibrosis | 1 | 2017 | 2048 | 0.020 |
Why?
|
Genes, Tumor Suppressor | 1 | 2014 | 1062 | 0.020 |
Why?
|
Lymphoma | 1 | 2019 | 1901 | 0.020 |
Why?
|
Interprofessional Relations | 1 | 2015 | 991 | 0.020 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2020 | 2911 | 0.020 |
Why?
|
Genes, p53 | 1 | 2011 | 712 | 0.020 |
Why?
|
Cystadenoma, Papillary | 1 | 2008 | 9 | 0.020 |
Why?
|
Patient Selection | 1 | 2021 | 4244 | 0.020 |
Why?
|
Radiographic Image Enhancement | 1 | 2013 | 876 | 0.020 |
Why?
|
Nitriles | 1 | 2014 | 971 | 0.020 |
Why?
|
Eye Diseases | 1 | 1994 | 655 | 0.020 |
Why?
|
Cystadenoma, Mucinous | 1 | 2008 | 62 | 0.020 |
Why?
|
Adenocarcinoma, Papillary | 1 | 2008 | 84 | 0.020 |
Why?
|
High-Throughput Nucleotide Sequencing | 1 | 2020 | 3638 | 0.020 |
Why?
|
In Situ Hybridization, Fluorescence | 1 | 2014 | 2509 | 0.020 |
Why?
|
Catecholamines | 1 | 2009 | 386 | 0.020 |
Why?
|
Intraoperative Period | 1 | 2009 | 511 | 0.020 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2015 | 3806 | 0.020 |
Why?
|
Membrane Proteins | 1 | 2004 | 7852 | 0.020 |
Why?
|
Gastroenterostomy | 1 | 2007 | 18 | 0.020 |
Why?
|
Watchful Waiting | 1 | 2011 | 491 | 0.020 |
Why?
|
Chronic Disease | 1 | 2022 | 9319 | 0.020 |
Why?
|
Image Processing, Computer-Assisted | 2 | 2014 | 8997 | 0.020 |
Why?
|
Vinblastine | 1 | 2008 | 488 | 0.020 |
Why?
|
Cell Survival | 1 | 2017 | 5792 | 0.020 |
Why?
|
Genome, Human | 1 | 2020 | 4423 | 0.020 |
Why?
|
Radiotherapy, Intensity-Modulated | 1 | 2013 | 801 | 0.020 |
Why?
|
Gene Deletion | 1 | 2014 | 2667 | 0.020 |
Why?
|
Epigenesis, Genetic | 1 | 2019 | 3793 | 0.020 |
Why?
|
Triiodobenzoic Acids | 1 | 2006 | 123 | 0.020 |
Why?
|
Menopause | 1 | 2014 | 1646 | 0.020 |
Why?
|
Breast | 1 | 2014 | 1966 | 0.020 |
Why?
|
Head and Neck Neoplasms | 1 | 2020 | 2891 | 0.020 |
Why?
|
Oligonucleotide Array Sequence Analysis | 1 | 2014 | 3777 | 0.020 |
Why?
|
Enzyme Activation | 1 | 2011 | 3592 | 0.020 |
Why?
|
Attention | 1 | 2015 | 2395 | 0.020 |
Why?
|
Mice, Inbred BALB C | 1 | 2014 | 6210 | 0.020 |
Why?
|
Hospitals, Urban | 1 | 2007 | 500 | 0.020 |
Why?
|
Clinical Trials as Topic | 1 | 2020 | 7999 | 0.010 |
Why?
|
Adipocytes | 1 | 2011 | 1192 | 0.010 |
Why?
|
Carcinoma, Neuroendocrine | 1 | 2008 | 339 | 0.010 |
Why?
|
Patient Care Team | 1 | 2015 | 2523 | 0.010 |
Why?
|
Propionates | 1 | 2005 | 183 | 0.010 |
Why?
|
Fluorodeoxyglucose F18 | 1 | 2013 | 2009 | 0.010 |
Why?
|
Receptor, Platelet-Derived Growth Factor beta | 1 | 2005 | 184 | 0.010 |
Why?
|
O(6)-Methylguanine-DNA Methyltransferase | 1 | 2004 | 83 | 0.010 |
Why?
|
Nursing Staff, Hospital | 1 | 2007 | 348 | 0.010 |
Why?
|
Child | 3 | 2021 | 80156 | 0.010 |
Why?
|
Health Services Accessibility | 1 | 2021 | 5439 | 0.010 |
Why?
|
Adrenergic beta-Antagonists | 1 | 2009 | 1241 | 0.010 |
Why?
|
Advisory Committees | 1 | 2007 | 785 | 0.010 |
Why?
|
Radiography | 1 | 2014 | 6966 | 0.010 |
Why?
|
Age Distribution | 1 | 2008 | 2880 | 0.010 |
Why?
|
TOR Serine-Threonine Kinases | 1 | 2011 | 2060 | 0.010 |
Why?
|
Hospitals, Teaching | 1 | 2007 | 1156 | 0.010 |
Why?
|
Cell Movement | 1 | 2014 | 5202 | 0.010 |
Why?
|
Phosphatidylinositol 3-Kinases | 1 | 2011 | 2859 | 0.010 |
Why?
|
Genes, ras | 1 | 2004 | 653 | 0.010 |
Why?
|
Reoperation | 1 | 2011 | 4302 | 0.010 |
Why?
|
Lymph Node Excision | 1 | 2007 | 1273 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2018 | 20092 | 0.010 |
Why?
|
Zebrafish | 1 | 2011 | 3005 | 0.010 |
Why?
|
Muscle, Skeletal | 1 | 2014 | 4927 | 0.010 |
Why?
|
Pilot Projects | 1 | 2012 | 8632 | 0.010 |
Why?
|
ROC Curve | 1 | 2006 | 3572 | 0.010 |
Why?
|
Nurses | 1 | 2007 | 2478 | 0.010 |
Why?
|
Transplantation, Heterologous | 1 | 2005 | 2385 | 0.010 |
Why?
|
Prostatic Neoplasms | 1 | 2019 | 11116 | 0.010 |
Why?
|
Smoking | 1 | 2013 | 9051 | 0.010 |
Why?
|
Blood Vessel Prosthesis Implantation | 1 | 2004 | 1427 | 0.010 |
Why?
|
Cosmids | 1 | 1994 | 105 | 0.010 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2014 | 15879 | 0.010 |
Why?
|
Chromosomes, Artificial, Yeast | 1 | 1994 | 113 | 0.010 |
Why?
|
Algorithms | 1 | 2015 | 14025 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2015 | 26108 | 0.010 |
Why?
|
Dinucleoside Phosphates | 1 | 1994 | 72 | 0.010 |
Why?
|
Critical Care | 1 | 2007 | 2697 | 0.010 |
Why?
|
Night Blindness | 1 | 1994 | 56 | 0.010 |
Why?
|
Phosphorylation | 1 | 2005 | 8312 | 0.010 |
Why?
|
Hospital Mortality | 1 | 2007 | 5291 | 0.010 |
Why?
|
Synovial Membrane | 1 | 1994 | 532 | 0.010 |
Why?
|
Retinitis Pigmentosa | 1 | 1994 | 397 | 0.010 |
Why?
|
Logistic Models | 1 | 2004 | 13251 | 0.010 |
Why?
|
DNA Primers | 1 | 1994 | 2820 | 0.010 |
Why?
|
Infant, Newborn | 1 | 2009 | 26211 | 0.010 |
Why?
|
Translocation, Genetic | 1 | 1994 | 1393 | 0.000 |
Why?
|
Infant | 1 | 2009 | 36202 | 0.000 |
Why?
|
Case-Control Studies | 1 | 2004 | 22124 | 0.000 |
Why?
|
Child, Preschool | 1 | 2009 | 42251 | 0.000 |
Why?
|
Phenotype | 1 | 2004 | 16603 | 0.000 |
Why?
|
Chromosome Mapping | 1 | 1994 | 4638 | 0.000 |
Why?
|
Polymerase Chain Reaction | 1 | 1994 | 6086 | 0.000 |
Why?
|
Base Sequence | 1 | 1994 | 12449 | 0.000 |
Why?
|
Molecular Sequence Data | 1 | 1994 | 17640 | 0.000 |
Why?
|